Does the media refer more to FHTX or ORIC?

In the previous week, Foghorn Therapeutics and Foghorn Therapeutics both had 5 articles in the media. Oric Pharmaceuticals' average media sentiment score of 1.77 beat Foghorn Therapeutics' score of 0.66 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Foghorn Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Oric Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor FHTX or OLMA?

In the previous week, Foghorn Therapeutics had 2 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 5 mentions for Foghorn Therapeutics and 3 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.61 beat Foghorn Therapeutics' score of 0.66 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Foghorn Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Olema Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to SANA or FHTX?

In the previous week, Foghorn Therapeutics had 1 more articles in the media than Sana Biotechnology. MarketBeat recorded 5 mentions for Foghorn Therapeutics and 4 mentions for Sana Biotechnology. Foghorn Therapeutics' average media sentiment score of 0.66 beat Sana Biotechnology's score of 0.47 indicating that Foghorn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Foghorn Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BIOA or FHTX?

In the previous week, BioAge Labs and BioAge Labs both had 5 articles in the media. Foghorn Therapeutics' average media sentiment score of 0.66 beat BioAge Labs' score of 0.20 indicating that Foghorn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Foghorn Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to XNCR or FHTX?

In the previous week, Xencor and Xencor both had 5 articles in the media. Foghorn Therapeutics' average media sentiment score of 0.66 beat Xencor's score of 0.66 indicating that Foghorn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Foghorn Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Foghorn Therapeutics (FHTX) Competitors

$5.38 -0.06 (-1.10%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$5.50 +0.12 (+2.23%)

As of 04:05 AM Eastern

Compare

FHTX vs. ORIC, OLMA, SANA, BIOA, and XNCR

Should you buy Foghorn Therapeutics stock or one of its competitors? MarketBeat compares Foghorn Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Foghorn Therapeutics include Oric Pharmaceuticals (ORIC), Olema Pharmaceuticals (OLMA), Sana Biotechnology (SANA), BioAge Labs (BIOA), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry.

How does Foghorn Therapeutics compare to Oric Pharmaceuticals?

Foghorn Therapeutics (NASDAQ:FHTX) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

Foghorn Therapeutics currently has a consensus price target of $11.43, suggesting a potential upside of 112.43%. Oric Pharmaceuticals has a consensus price target of $19.27, suggesting a potential upside of 82.68%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Foghorn Therapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Foghorn Therapeutics has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$30.91M	10.22	-$74.28M	-$1.16	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A

Oric Pharmaceuticals has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-266.88%	N/A	-35.38%
Oric Pharmaceuticals	N/A	-35.33%	-33.31%

Foghorn Therapeutics has a beta of 2.86, meaning that its share price is 186% more volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market.

61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 9.0% of Foghorn Therapeutics shares are owned by company insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Foghorn Therapeutics and Foghorn Therapeutics both had 5 articles in the media. Oric Pharmaceuticals' average media sentiment score of 1.77 beat Foghorn Therapeutics' score of 0.66 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Foghorn Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Oric Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Foghorn Therapeutics beats Oric Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Olema Pharmaceuticals?

Foghorn Therapeutics (NASDAQ:FHTX) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Foghorn Therapeutics has a beta of 2.86, indicating that its share price is 186% more volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2, indicating that its share price is 100% more volatile than the broader market.

In the previous week, Foghorn Therapeutics had 2 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 5 mentions for Foghorn Therapeutics and 3 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.61 beat Foghorn Therapeutics' score of 0.66 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Foghorn Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Olema Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Olema Pharmaceuticals has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-266.88%	N/A	-35.38%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 9.0% of Foghorn Therapeutics shares are owned by company insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Foghorn Therapeutics has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$30.91M	10.22	-$74.28M	-$1.16	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

Foghorn Therapeutics currently has a consensus price target of $11.43, suggesting a potential upside of 112.43%. Olema Pharmaceuticals has a consensus price target of $44.10, suggesting a potential upside of 272.15%. Given Olema Pharmaceuticals' higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Foghorn Therapeutics beats Olema Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

Foghorn Therapeutics has higher revenue and earnings than Sana Biotechnology. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Foghorn Therapeutics	$30.91M	10.22	-$74.28M	-$1.16	N/A

88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Sana Biotechnology presently has a consensus price target of $9.50, suggesting a potential upside of 166.11%. Foghorn Therapeutics has a consensus price target of $11.43, suggesting a potential upside of 112.43%. Given Sana Biotechnology's higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Foghorn Therapeutics had 1 more articles in the media than Sana Biotechnology. MarketBeat recorded 5 mentions for Foghorn Therapeutics and 4 mentions for Sana Biotechnology. Foghorn Therapeutics' average media sentiment score of 0.66 beat Sana Biotechnology's score of 0.47 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Foghorn Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Sana Biotechnology has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Foghorn Therapeutics	-266.88%	N/A	-35.38%

Sana Biotechnology has a beta of 2.13, suggesting that its stock price is 113% more volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.86, suggesting that its stock price is 186% more volatile than the broader market.

Summary

Foghorn Therapeutics beats Sana Biotechnology on 9 of the 16 factors compared between the two stocks.

How does Foghorn Therapeutics compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

Foghorn Therapeutics has a net margin of -266.88% compared to BioAge Labs' net margin of -871.75%. Foghorn Therapeutics' return on equity of 0.00% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
Foghorn Therapeutics	-266.88%	N/A	-35.38%

Foghorn Therapeutics has higher revenue and earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$10.32M	98.16	-$80.61M	-$2.40	N/A
Foghorn Therapeutics	$30.91M	10.22	-$74.28M	-$1.16	N/A

61.6% of Foghorn Therapeutics shares are owned by institutional investors. 20.8% of BioAge Labs shares are owned by insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BioAge Labs has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.86, suggesting that its stock price is 186% more volatile than the broader market.

BioAge Labs currently has a consensus price target of $43.50, suggesting a potential upside of 90.96%. Foghorn Therapeutics has a consensus price target of $11.43, suggesting a potential upside of 112.43%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Foghorn Therapeutics is more favorable than BioAge Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, BioAge Labs and BioAge Labs both had 5 articles in the media. Foghorn Therapeutics' average media sentiment score of 0.66 beat BioAge Labs' score of 0.20 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Foghorn Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Foghorn Therapeutics beats BioAge Labs on 12 of the 15 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Xencor?

Xencor (NASDAQ:XNCR) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Xencor has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.86, meaning that its share price is 186% more volatile than the broader market.

In the previous week, Xencor and Xencor both had 5 articles in the media. Foghorn Therapeutics' average media sentiment score of 0.66 beat Xencor's score of 0.66 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Foghorn Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

61.6% of Foghorn Therapeutics shares are owned by institutional investors. 5.1% of Xencor shares are owned by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Foghorn Therapeutics has lower revenue, but higher earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	8.83	-$91.92M	-$2.29	N/A
Foghorn Therapeutics	$30.91M	10.22	-$74.28M	-$1.16	N/A

Xencor has a net margin of -177.10% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
Foghorn Therapeutics	-266.88%	N/A	-35.38%

Xencor currently has a consensus price target of $24.25, indicating a potential upside of 62.21%. Foghorn Therapeutics has a consensus price target of $11.43, indicating a potential upside of 112.43%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Foghorn Therapeutics is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Foghorn Therapeutics beats Xencor on 12 of the 15 factors compared between the two stocks.

Get Foghorn Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FHTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FHTX vs. The Competition

Export

Metric	Foghorn Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$319.40M	$3.68B	$6.86B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-4.64	20.98	26.94	24.38
Price / Sales	10.22	311.10	521.23	91.92
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	-2.80	8.54	10.89	6.33
Net Income	-$74.28M	$23.83M	$3.59B	$331.02M
7 Day Performance	-12.80%	-2.77%	-1.53%	-0.33%
1 Month Performance	30.90%	5.85%	2.72%	-1.29%
1 Year Performance	-7.24%	52.15%	28.47%	21.30%

Foghorn Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FHTX Foghorn Therapeutics	2.7695 of 5 stars	$5.38 -1.1%	$11.43 +112.4%	-8.5%	$319.40M	$30.91M	N/A	120	News Coverage Analyst Downgrade
ORIC Oric Pharmaceuticals	2.451 of 5 stars	$10.88 -0.3%	$18.92 +73.9%	-2.8%	$1.13B	N/A	N/A	80	News Coverage
OLMA Olema Pharmaceuticals	2.42 of 5 stars	$12.63 -1.1%	$44.10 +249.2%	+145.3%	$1.12B	N/A	N/A	70	News Coverage Analyst Upgrade
SANA Sana Biotechnology	2.9604 of 5 stars	$4.12 +3.8%	$9.50 +130.6%	-15.4%	$1.10B	N/A	N/A	380	Analyst Upgrade
BIOA BioAge Labs	2.4001 of 5 stars	$24.40 -1.8%	$43.50 +78.3%	+392.0%	$1.10B	$8.99M	N/A	N/A	News Coverage Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FHTX) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Foghorn Therapeutics (FHTX) Competitors

FHTX vs. ORIC, OLMA, SANA, BIOA, and XNCR

How does Foghorn Therapeutics compare to Oric Pharmaceuticals?

Summary

How does Foghorn Therapeutics compare to Olema Pharmaceuticals?

Summary

How does Foghorn Therapeutics compare to Sana Biotechnology?

Summary

How does Foghorn Therapeutics compare to BioAge Labs?

Summary

How does Foghorn Therapeutics compare to Xencor?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX vs. The Competition

Foghorn Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Foghorn Therapeutics (FHTX) Competitors

FHTX vs. ORIC, OLMA, SANA, BIOA, and XNCR

How does Foghorn Therapeutics compare to Oric Pharmaceuticals?

Do analysts prefer FHTX or ORIC?

Which has stronger earnings and valuation, FHTX or ORIC?

Is FHTX or ORIC more profitable?

Which has more risk and volatility, FHTX or ORIC?

Do institutionals and insiders hold more shares of FHTX or ORIC?

Does the media refer more to FHTX or ORIC?

Summary

How does Foghorn Therapeutics compare to Olema Pharmaceuticals?

Which has more volatility & risk, FHTX or OLMA?

Does the media favor FHTX or OLMA?

Is FHTX or OLMA more profitable?

Do insiders & institutionals hold more shares of FHTX or OLMA?

Which has better valuation & earnings, FHTX or OLMA?

Do analysts prefer FHTX or OLMA?

Summary

How does Foghorn Therapeutics compare to Sana Biotechnology?

Which has higher earnings & valuation, SANA or FHTX?

Do insiders & institutionals hold more shares of SANA or FHTX?

Do analysts recommend SANA or FHTX?

Does the media refer more to SANA or FHTX?

Is SANA or FHTX more profitable?

Which has more risk and volatility, SANA or FHTX?

Summary

How does Foghorn Therapeutics compare to BioAge Labs?

Is BIOA or FHTX more profitable?

Which has preferable valuation & earnings, BIOA or FHTX?

Do institutionals & insiders have more ownership in BIOA or FHTX?

Which has more risk and volatility, BIOA or FHTX?

Do analysts recommend BIOA or FHTX?

Does the media favor BIOA or FHTX?

Summary

How does Foghorn Therapeutics compare to Xencor?

Which has more risk and volatility, XNCR or FHTX?

Does the media refer more to XNCR or FHTX?

Do institutionals & insiders believe in XNCR or FHTX?

Which has higher earnings and valuation, XNCR or FHTX?

Is XNCR or FHTX more profitable?

Do analysts prefer XNCR or FHTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX vs. The Competition

Foghorn Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools